Comment on "GLM7 - A Novel Composite Glycolipid Index Derived from Routine Health Indicators for Enhanced Diagnosis and Prediction of Multimorbidity"
- PMID: 41816970
- DOI: 10.1002/advs.74808
Comment on "GLM7 - A Novel Composite Glycolipid Index Derived from Routine Health Indicators for Enhanced Diagnosis and Prediction of Multimorbidity"
References
-
- Z. Wang, S. Chen, X. Feng, et al., “GLM7 – A Novel Composite Glycolipid Index Derived from Routine Health Indicators for Enhanced Diagnosis and Prediction of Multimorbidity,” Advanced Science 12 (2025): 10552, https://doi.org/10.1002/advs.202510552.
-
- L. P. Lin and M. T. T. Tan, “Biosensors for the Detection of Lung Cancer Biomarkers: a Review on Biomarkers, Transducing Techniques and Recent Graphene‐Based Implementations,” Biosensors and Bioelectronics 237 (2023): 115492, https://doi.org/10.1016/j.bios.2023.115492.
-
- G. Yang, Z. Xiao, C. Tang, Y. Deng, H. Huang, and Z. He, “Recent Advances in Biosensor for Detection of Lung Cancer Biomarkers,” Biosensors and Bioelectronics 141 (2019): 111416, https://doi.org/10.1016/j.bios.2019.111416.
-
- S. A. Noonan, T. Patil, D. Gao, et al., “Baseline and on‐Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene‐Addicted Adenocarcinoma of the Lung,” Journal of Thoracic Oncology 13 (2018): 134–138, https://doi.org/10.1016/j.jtho.2017.08.005.
-
- D. Albanes, K. Alcala, N. Alcala, et al., “The Blood Proteome of Imminent Lung Cancer Diagnosis,” Nature Communications 14 (2023): 3042, https://doi.org/10.1038/s41467‐023‐37979‐8.